Table 2. Infection events in study population (n = 1083).

Mention term	With cetuximab (n = 158)	Without cetuximab (n = 925)	P-value
	n%	n%
			<0.001
1.Laryngitis	1(0.6)	0
3.Pneumonia	19(12)	39(4.2)
4.Bronchitis	3(1.9)	9(1.0)
5.Fever	0	4(0.4)
6.Urinary tract infection	1(0.6)	0
8.Viral infection	0	1(0.1)
11.Herpes zoster	2(1.3)	0
12.Septicemia	3(1.9)	14(1.5)
15.Diverticulitis	1(0.6)	0
17.Otitis media	0	1(0.1)
18.Tonsillitis	0	3(0.3)
19.Pharyngitis,epiglottitis, laryngopharyngitis	0	1(0.1)
20.Tuberculosis	0	1(0.1)
28.Pancreatitis	0	1(0.1)
30.Acute upper respiratory infections	0	1(0.1)
33.Cellulitis	1(0.6)	11(1.2)
35.Infectious disease and parasitic disease	0	3(0.4)
36.Others	1(0.6)	4(0.4)
Infection (total = 125)	32(20.3)	93(10.1)